Cogent Biosciences, Inc.
COGT
$39.16
$0.180.46%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -294.37M | -284.08M | -269.50M | -255.86M | -242.30M |
| Total Depreciation and Amortization | 4.55M | 4.50M | 4.42M | 4.35M | 4.04M |
| Total Amortization of Deferred Charges | 363.00K | -- | -- | -- | -- |
| Total Other Non-Cash Items | 36.80M | 30.58M | 33.18M | 32.12M | 29.31M |
| Change in Net Operating Assets | 6.75M | 15.38M | 10.12M | 11.60M | 17.67M |
| Cash from Operations | -245.92M | -233.61M | -221.77M | -207.79M | -191.28M |
| Capital Expenditure | -818.00K | -1.03M | -1.05M | -573.00K | -813.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -14.27M | 201.18M | 107.66M | 38.85M | -12.09M |
| Cash from Investing | -15.09M | 200.15M | 106.61M | 38.28M | -12.91M |
| Total Debt Issued | 49.29M | 49.29M | -- | -- | -- |
| Total Debt Repaid | 0.00 | -2.07M | -- | -- | -- |
| Issuance of Common Stock | 257.70M | 26.43M | 37.06M | 226.15M | 226.03M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -5.80M | 10.80M | -100.00K | -100.00K | -11.60M |
| Cash from Financing | 289.59M | 72.85M | 25.36M | 214.45M | 214.43M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 28.59M | 39.38M | -89.80M | 44.94M | 10.24M |